Akèy › Kansè Poumon ki pa ti selil › Florid › Orlando
Etid klinik pou Kansè Poumon ki pa ti selil nan Orlando, FL
44 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Orlando (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Advent Health, Orlando
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #48, Celebration · 17 mi lwen
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16 mi lwen
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Ap rekriteFaz 3
- Clermont Oncology Center, Clermont · 24 mi lwen
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- AdventHealth Cancer Institute, Orlando
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- AdventHealth, Orlando
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Florida Cancer Specialists, Orlando
- Orlando Health Ambulatory Care Center, Orlando
- Orlando Health Cancer Institute, Orlando
- ak 4 plis
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Orlando Health Cancer Institute, Orlando
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Ap rekriteFaz 1/2
- Orlando Health Ambulatory Care Center, Orlando
- Orlando Health Cancer Institute, Orlando
- Orlando Health Orlando Regional Medical Center, Orlando
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Orlando
- Research Site, Clermont · 24 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Clermont Oncology Center, Clermont · 24 mi lwen
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Sara Cannon Research Institute Lake Nona, Orlando
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Ap rekriteFaz 1
- AdventHealth, Orlando
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Orlando
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
- Advent Health Medical Group Radiation Oncology at Central Florida, Orlando
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- AdventHealth Orlando, Orlando
- Local Institution - 007-896-A, Celebration · 17 mi lwen
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona, Orlando
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Orlando Health Cancer Institute, Orlando
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Ap rekriteFaz 1
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando
SMP-3124LP in Adults With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Advent Health, Celebration · 17 mi lwen
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- AdventHealth Celebration, Celebration · 17 mi lwen
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- Sarah Cancer Research Institution - Florida Cancer Specialist, Orlando
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Ap rekriteFaz 1/2
- Clermont Oncology Center, Clermont · 24 mi lwen
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Ap rekriteFaz 1
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Florida Cancer Specialists, Orlando
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Florida Cancer Specialists, Orlando
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- Orlando Health Cancer Institute, Orlando
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Orlando
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- AdventHealth Celebration, Celebration · 17 mi lwen
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Ap rekriteFaz 2
- Clermont Oncology Center, Clermont · 24 mi lwen
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Ap rekriteFaz 3
- Advent Health, Orlando
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- AdventHealth Cancer Institute, Celebration · 17 mi lwen
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Clermont Oncology Center, Clermont · 24 mi lwen
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Florida Cancer Specialists & Research Institute, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Orlando
- Obèsite31 etid
- Kansè Metastatik29 etid
- Sipwa27 etid
- Maladi Alzheimer25 etid
- Dyabèt Tip 224 etid
- Kansè (tout kalite)24 etid
- Kansè nan tete23 etid
- Kansè ovè22 etid
- Kolit Ulseratif22 etid
- Kansè poumon21 etid
- Kansè kolorektal19 etid
- Twoub depresif majè19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.